US Stock MarketDetailed Quotes
OTLK Outlook Therapeutics
- 5.130
- -0.150-2.84%
Close Nov 21 16:00 ET
- 5.130
- 0.0000.00%
Post 20:01 ET
121.35MMarket Cap-870P/E (TTM)
5.290High5.060Low215.40KVolume5.220Open5.280Pre Close1.11MTurnover1.55%Turnover RatioLossP/E (Static)23.66MShares12.85052wk High-1.45P/B71.51MFloat Cap4.61052wk Low--Dividend TTM13.94MShs Float219.200Historical High--Div YieldTTM4.36%Amplitude4.004Historical Low5.151Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Outlook Therapeutics Stock Forum
6 MINUTES AGO, 8:05 AM EST
VIA GLOBENEWSWIRE
Outlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD
Outlook Therapeutics has received European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma), an ophthalmic formulation for treating wet AMD. This makes it the first ophthalmic bevacizumab formulation approved for wet AMD in the EU. This authorization covers all 27 EU Member States and will extend to Icela...
In an era where medical advancements are pivotal to enhancing quality of life, a significant breakthrough has been made in the treatment of wet age-related macular degeneration (AMD), a leading cause of vision loss among the elderly. Outlook Therapeutics, Inc. has received a positive opinion from the European Union's Committee for Me...
No comment yet